Show simple item record

dc.contributor.authorHaynes, BPen_US
dc.contributor.authorGinsburg, Oen_US
dc.contributor.authorGao, Qen_US
dc.contributor.authorFolkerd, Een_US
dc.contributor.authorAfentakis, Men_US
dc.contributor.authorQuang, LHen_US
dc.contributor.authorHan, PTen_US
dc.contributor.authorKhoa, PHen_US
dc.contributor.authorDinh, NVen_US
dc.contributor.authorTo, TVen_US
dc.contributor.authorClemons, Men_US
dc.contributor.authorSmith, IEen_US
dc.contributor.authorDowsett, Men_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2017-12-19T14:32:42Z
dc.date.issued2017en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29214214en_US
dc.identifier49en_US
dc.identifier.citationNPJ Breast Cancer, 2017, 3 pp. 47 - ?en_US
dc.identifier.issn2374-4677en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/978
dc.identifier.doi10.1038/s41523-017-0049-zen_US
dc.description.abstractFor premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breast tumour biology. We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER + breast cancer for 2 weeks prior to mastectomy. Plasma estradiol concentrations decreased from 406 ± 41 to 20.7 ± 2.6 pmol/l (mean ± sem) 24 h after OvX, and to 8.1 ± 0.8 pmol/l 2 weeks later at mastectomy. Ki67 decreased in 33/36 (91.7%) tumours. The expression of 655 genes changed significantly (FDR < 1%) with an absolute mean fold-change (FC) ≥ 1.25 (257 up, 398 down). Archetypal oestrogen-regulated genes (TFF1, GREB1, PGR and PDZK1) showed large decreases in expression (FC = 0.20-0.69; p < 1e-6-1e-7). Proliferation-associated genes (e.g. TOP2A, AURKA and UBE2C) were also strongly downregulated (FC = 0.38-0.56; p < 1e-7) along with putative progesterone-regulated genes (e.g. FKBP4, MYB; FC = 0.64-0.68; p < 1e-4-1e-7). The gene expression changes did not differ according to HER2 status and correlated strongly with the changes reported previously after aromatase inhibitor (AI) treatment in postmenopausal women (rho = 0.55, p < 1e-04). However, after OvX the mean FC was significantly higher compared to AI (p < 1e-04). In conclusion, changes in tumoural gene expression after OvX were largely similar, but of a greater magnitude to those observed after AI in postmenopausal patients; however, OvX appeared to have a greater effect on progesterone-regulated genes than AI.en_US
dc.format.extent47 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleMolecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-11-01en_US
rioxxterms.versionofrecord10.1038/s41523-017-0049-zen_US
rioxxterms.licenseref.startdate2017en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNPJ Breast Canceren_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished onlineen_US
pubs.volume3en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorFolkerd, Elizabethen_US
dc.contributor.icrauthorGao, Qiongen_US
dc.contributor.icrauthorDowsett, Mitchen_US
dc.contributor.icrauthorSmith, Ianen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/